

MSK.P-031USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Application No. : 09/381,556
Application of: : Fong et al.
International Application No. : PCT/US98/05505
International Filing Date : 20/03/1998
Priority Date Claimed : 21/03/1997
For: : Rapid Production of Autologous Tumor Vaccines by
Using HSV Amplicon Vectors
Attorney Docket No. : MSK.P-031USNP

SUBSTITUTE FORM 1449

U.S. Patents


Examiner's initials	Patentee	Patent No.	Issue Date	Class	Sub-class	Filing date if appropriate

Foreign Patents

Examiner's initials	Country	Patent No.	Publication date	Class	Sub-class	Translation
AW	WO	96 29421	Sept. 26, 1996			
	WO	97 00085	Jan. 3, 1997			

Other Publications

Examiner's initials	Description
AW	KUTUBUDDIN ET AL: "ERADICATION OF PREEXISTING MURINE TUMOR USING HERPES AMPLICON VECTORS", CANCER GENE THERAPY, Vo. 4, No. 6 November 1997 -- December 1997, page S26 XP002073450;
	Parijs et al. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science Vol. 280 pages 243-248. 1998.
	Vieweg et al. considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Investigation Vol. 13 pages 193-201. 1995.



MSK.P-031USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Application No. : 09/381,556
Application of: : Fong et al.
International Application No. : PCT/US98/05505
International Filing Date : 20/03/1998
Priority Date Claimed : 21/03/1997
For: : Rapid Production of Autologous Tumor Vaccines by
Using HSV Amplicon Vectors
Attorney Docket No. : MSK.P-031USNP

SUBSTITUTE FORM 1449

U.S. Patents


Examiner's initials	Patentee	Patent No.	Issue Date	Class	Sub-class	Filing date if appropriate

Foreign Patent Documents

Examiner's initials	Country	Patent No.	Publication date	Class	Sub-class	Translation
MO	WO	97/00085	January 1997			
U	WO	96/29421	September 1996			

Other Publications

Examiner's initials	Description
MO	Tung, et al., "Rapid Production of Interleukin-2-Secreting Tumor Cells by Herpes Simplex Virus-Mediated Gene Transfer: Implications for Autologous Vaccine Production.", vol. 7, 1996, pages 2217-2224.
	Kutubuddin, et al., "Eradication of preexisting murine tumor using herpes amplicon vectors.", vol 4, no. 6, November 1997 - December 1997, page S26.
	Dranoff, et al., "Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.", 1993, pages 3539-3543.
	Karpoff, et al., "Prevention of Hepatic Tumor Metastases in Rats with Herpes Viral Vaccines and γ -Interferon.", vol. 99, no. 4, February 1997, pages 799-804.
	Vieweg, et al., "Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines.", Medline for Cancer Res 54: 1760-1765 (1994).



MO	Iwanuma, et al., "Induction of tumor-specific cytotoxic T lymphocytes and natural killer cells by tumor cells transfected with the interleukin-2 gene.", Medline for Cancer Immunol Immunother 40: 17-23 (1995).
f	Abe, et al., "Antitumor effect induced by granulocyte/macrophage-colony-stimulating factor gene-modified tumor vaccination: comparison of adenovires- and retrovirus-mediated genetic transduction." Medline for J Cancer Res Clin Oncol 121: 587-592 (1995).

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner Allwell Date Considered 10/18/02



MSK.P-031USNP

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

U.S. Application No. : 09/381,556
Application of: : Fong et al.
International Application No. : PCT/US98/05505
International Filing Date : 20/03/1998
Priority Date Claimed : 21/03/1997
For: : Rapid Production of Autologous Tumor Vaccines by
Using HSV Amplicon Vectors
Attorney Docket No. : MSK.P-031USNP

SUBSTITUTE FORM 1449

U.S. Patents



Examiner's initials	Patentee	Patent No.	Issue Date	Class	Sub-class	Filing date if appropriate

Foreign Patents

Examiner's initials	Country	Patent No.	Publication date	Class	Sub-class	Translation
me	WO	96 29421	Sept. 26, 1996			
d	WO	97 00085	Jan. 3, 1997			

Other Publications

Examiner's initials	Description
me	KUTUBUDDIN ET AL. "ERADICATION OF PREEXISTING MURINE TUMOR USING HERPES AMPLICON VECTORS", CANCER GENE THERAPY, Vol. 4, No. 6 November 1997 -- December 1997, page S26 XP002073450;
d	Parijs et al. Homeostasis and self-tolerance in the immune system: Turning lymphocytes off. Science Vol. 280 pages 243-248. 1998.
d	Vieweg et al. considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Investigation Vol. 13 pages 193-201. 1995.

	Hellstrom et al. Tumor vaccines: A reality at last? Journal of Immunotherapy Vol. 21 pages 119-126. 1998.
	Stevenson Tumor Vaccines FASEB J. Vol. 5 pages 2250-2257

This Information Disclosure Citation List is being submitted as a substitute for Form PTO-1449. The Examiner is requested to place his or her initials on the lines adjacent to the citations to indicate that the reference has been considered. The Examiner is further requested to fill in his or her name and the date the information was considered in blocks at the bottom of this substitute for Form PTO-1449.

Examiner Neil D. G. Date Considered 10/18/02

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**